Abstract：
Drug repurposing can be cheaper and faster than developing new compounds. Yet, it remains underused, partially because of regulatory and intellectual property challenges. Policy-makers in the United States and Europe have created seven drug development programs that aim to overcome these challenges using a variety of different strategies.
摘要：
药物再利用可以比开发新化合物更便宜和更快。然而，它仍然未被充分利用，部分原因是监管和知识产权挑战。美国和欧洲的政策制定者制定了七个药物开发计划，旨在使用各种不同的策略来克服这些挑战。
